VPHIF (Valeo Pharma) ROC %: -18.32% (As of Jul. 2024)


VPHIF Valeo Pharma Inc VPHIF
12 GF Score
Price $0.00
View Full Analysis

What is Valeo Pharma ROC %?

Valeo Pharma VPHIF -99.00% 12 ROC % is -18.32% as of Jul. 2024. GuruFocus rates VPHIF with a GF Score™ of 12/100.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Valeo Pharma's annualized return on capital (ROC %) for the quarter that ended in Jul. 2024 was -18.32%.

As of today (2026-06-24), Valeo Pharma's WACC % is 0.00%. Valeo Pharma's ROC % is 0.00% (calculated using TTM income statement data). Valeo Pharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Valeo Pharma  (OTCPK:VPHIF) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Valeo Pharma's WACC % is 0.00%. Valeo Pharma's ROC % is 0.00% (calculated using TTM income statement data). Valeo Pharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Valeo Pharma ROC % Related Terms


Valeo Pharma ROC % Historical Data

* Premium members only.

The historical data trend for Valeo Pharma's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valeo Pharma ROC % Chart

Valeo Pharma Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
ROC %
Get a 7-Day Free Trial -97.81 -86.16 -131.13 -94.97 -71.53

Valeo Pharma Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -59.64 -121.37 -51.60 -31.04 -18.32
VPHIF
12GF Score
Valeo Pharma Inc VPHIF
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valeo Pharma ROC % Calculation

Valeo Pharma's annualized Return on Capital (ROC %) for the fiscal year that ended in Oct. 2023 is calculated as:

ROC % (A: Oct. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Oct. 2022 ) + Invested Capital (A: Oct. 2023 ))/ count )
=-12.564 * ( 1 - 0% )/( (17.025 + 18.103)/ 2 )
=-12.564/17.564
=-71.53 %

where

Valeo Pharma's annualized Return on Capital (ROC %) for the quarter that ended in Jul. 2024 is calculated as:

ROC % (Q: Jul. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Apr. 2024 ) + Invested Capital (Q: Jul. 2024 ))/ count )
=-7.532 * ( 1 - 0% )/( (35.281 + 46.949)/ 2 )
=-7.532/41.115
=-18.32 %

where

Note: The Operating Income data used here is four times the quarterly (Jul. 2024) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -18.32% mean?
Valeo Pharma (VPHIF) has a ROC % of -18.32% as of Jul. 2024. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Valeo Pharma and its competitors.
Is Valeo Pharma's ROC % too high?
Valeo Pharma's current ROC % is -18.32%. Overall, Valeo Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Valeo Pharma's ROC % compare to ZTS?
Valeo Pharma's ROC % of -18.32% can be compared against companies in the Drug Manufacturers industry. The industry median ROC % is 4.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Drug Manufacturers company?
The median ROC % among Drug Manufacturers companies is 4.44, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Valeo Pharma and its competitors. For the Drug Manufacturers industry, the median ROC % is 4.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valeo Pharma's current ROC % is -18.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valeo Pharma stock overvalued right now?
Valeo Pharma (VPHIF) has a current ROC % of -18.32%. The current ROC % is -18.32%. Valeo Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Valeo Pharma (VPHIF), the current ROC % is -18.32% as of Jul. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Valeo Pharma Business Description

Address 16667, Hymus Boulevard, Kirkland, QC, CAN, H9H 4R9
Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and hospital specialty products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.
12GF Score

Get the complete analysis for VPHIF

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price